Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) Starts Presentation at 29th Annual ROTH Conference
Aerie Pharmaceuticals (NASDAQ: AERI) is a clinical stage pharmaceutical company focusing on the discovery of innovative treatments for glaucoma and other eye ailments. Its leading product candidates, Rhopressa™ and Roclatan™, are believed to be effective for most glaucoma patients, based on clinical trials results, and are currently in different stages of development in view of commercialization. Aerie is also focused on the development of additional product candidates and technologies in ophthalmology. For more information, visit the company’s website at www.aeriepharma.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication…